Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 147, Issue 6, 2008, Pages 990-995

  Roffman, Joshua L ^a   Weiss, Anthony P ^a   Deckersbach, Thilo ^a   Freudenreich, Oliver ^a   Henderson, David C ^a   Wong, Donna H ^b   Halsted, Charles H ^b   Goff, Donald C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

COMT; Executive function; Methylation; MTHFR; Schizophrenia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOL METHYLTRANSFERASE; DOPAMINE; METHIONINE; NEUROLEPTIC AGENT; VALINE;

ADULT; ARTICLE; BRAIN FUNCTION; COGNITIVE DEFECT; DNA METHYLATION; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; FEMALE; HERITABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; PERSEVERATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; TASK PERFORMANCE; WISCONSIN CARD SORTING TEST;

ADULT; AMINO ACID SUBSTITUTION; CATECHOL O-METHYLTRANSFERASE; COGNITION; DNA METHYLATION; DOPAMINE; EPIGENESIS, GENETIC; FEMALE; GENOTYPE; HUMANS; MALE; METHIONINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MODELS, BIOLOGICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYNAPTIC TRANSMISSION; VALINE;

EID: 51449089365     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30684     Document Type: Article

References (46)

1. Abdolmaleky HM, Smith CL, Faraone SV, Shafa R, Stone W, Glatt SJ, Tsuang MT. 2004. Methylomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet Part B 127B(1):51-59.
2. Abdolmaleky HM, Cheng KH, Faraone SV, Wilcox M, Glatt SJ, Gao F, Smith CL, Shafa R, Aeali B, Carnevale J, et al. 2006. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 15(21):3132-3145.
3. Barnett JH, Jones PB, Robbins TW, Muller U. 2007. Effects of the catechol-O-methyltransferase Val(158)Met polymorphism on executive function: A meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Biol Psychiatry 60(2):141-151.
4. Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicott JH, et al. 2004. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 161(10):1798-1805.
5. Bertolino A, Blasi G, Latorre V, Rubino V, Rampino A, Sinibaldi L, Caforio G, Petruzzella V, Pizzuti A, Scarabino T, et al. 2006. Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain. J Neurosci 26(15):3918-3922.
6. Caldu X, Vendrell P, Bartres-Faz D, Clemente I, Bargallo N, Jurado MA, Serra-Grabulosa JM, Junque C. 2007. Impact of the COMT Val(108/158) Met and DAT genotypes on prefrontal function in healthy subjects. Neuroimage 37(4):1437-1444.
7. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, et al. 2004. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75(5):807-821.
8. Deth RC. 2003. Molecular origins of human attention: The dopamine-folate connection. New York: Springer-Verlag.
9. Diaz-Asper CM, Goldberg TE, Kolachana BS, Straub RE, Egan MF, Weinberger DR. 2007. Genetic Variation in Catechol-O-Methyltransferase: Effects on Working Memory in Schizophrenic Patients, Their Siblings, and Healthy Controls. Biol Psychiatry (in press).
10. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR. 2001. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98(12):6917-6922.
11. Elliott GR, Sutherland K, Erdelyi E, Ciaranello RD, Barchas JD, Wyatt RJ. 1978. N5,10-methylenetetrahydrofolate reductase activity in autopsied brain parts of chronic schizophrenics and controls and in vitro tryptoline formation. Biol Psychiatry 13(6):695-708.
12. Fan JB, Zhang CS, Gu NF, Li XW, Sun WW, Wang HY, Feng GY, St Clair D, He L. 2005. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis. Biol Psychiatry 57(2):139-144.
13. Freeman JM, Finkelstein JD, Mudd SH. 1975. Folate-responsive homocystinuria and "schizophrenia". A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity. N Engl J Med 292(10):491-496.
14. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, Olivieri O, Jacques PF, Rosenberg IH, Corrocher R, et al. 2002. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 99(8):5606-5611.
15. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al. 1995. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111-113.
16. Gilbody S, Lewis S, Lightfoot T. 2007. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE review. Am J Epidemiol 165(1):1-13.
17. Goldberg TE, Torrey EF, Berman KF, Weinberger DR. 1994. Relations between neuropsychological performance and brain morphological and physiological measures in monozygotic twins discordant for schizophrenia. Psychiatry Res 55(1):51-61.
18. Goldman-Rakic PS. 1996. Regional and cellular fractionation of working memory. Proc Natl Acad Sci USA 93(24):13473-13480.
19. Gur RE, Calkins ME, Gur RC, Horan WP, Nuechterlein KH, Seidman LJ, Stone WS. 2007. The consortium on the genetics of schizophrenia: Neurocognitive endophenotypes. Schizophr Bull 33(1):49-68.
20. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
21. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. 1993. Wisconsin Card Sorting Test manual (Revised and expanded). Odessa: Psychological Assessment Resources.
22. Ho BC, Wassink TH, O'Leary DS, Sheffield VC, Andreasen NC. 2005. Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: Working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol Psychiatry 10229:287-298.
23. Hong X, Hsu YH, Terwedow H, Tang G, Liu X, Jiang S, Xu X, Xu X. 2007. Association of the methylenetetrahydrofolate reductase C677T polymorphism and fracture risk in Chinese postmenopausal women. Bone 40(3):737-742.
24. Joober R, Gauthier J, Lal S, Bloom D, Lalonde P, Rouleau G, Benkelfat C, Labelle A. 2002. Catechol-O-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test. Arch Gen Psychiatry 59(7):662-663.
25. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261-276.
26. Kreisler O, Liebert E, Horwitt MK. 1948. Psychiatric observations on induced vitamin B complex deficiency in psychotic patients. Am J Psychiatry 105:102-106.
27. Laws KR. 1999. A meta-analytic review of Wisconsin Card Sort studies in schizophrenia: General intellectual deficit in disguise? Cognit Neuropsychiatry 4(1):1-30.
28. Lombardi WJ, Andreason PJ, Sirocco KY, Rio DE, Gross RE, Umhau JC, Hommer DW. 1999. Wisconsin Card Sorting Test performance following head injury: Dorsolateral fronto-striatal circuit activity predicts perseveration. J Clin Exp Neuropsychol 21(1):2-16.
29. Matthysse S, Baldessarini RJ. 1972. S-adenosylmethionine and catechol-O-methyl-transferase in schizophrenia. Am J Psychiatry 128(10):1310-1312.
30. Mill J, Dempster E, Caspi A, Williams B, Moffitt T, Craig I. 2006. Evidence for monozygotic twin (MZ) discordance in methylation level at two CpG sites in the promoter region of the catechol-O-methyltransferase (COMT) gene. Am J Med Genet Part B 141B(4):421-425.
31. Munafo MR, Bowes L, Clark TG, Flint J. 2005. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: A meta-analysis of case-control studies. Mol Psychiatry 10(8):765-770.
32. Nicodemus KK, Kolachana BS, Vakkalanka R, Straub RE, Giegling I, Egan MF, Rujescu D, Weinberger DR. 2007. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: Influence on risk of schizophrenia. Hum Genet 120(6): 889-906.
33. Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, Henderson DC, Purcell S, Wong DH, Halsted CH, Goff DC. 2007a. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophr Res 92(1-3):181-188.
34. Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, Bottiglieri T, Wong DH, Halsted CH, Goff DC. 2007b. Contribution of methylenetetrahyrdofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry (in press).
35. Rosa A, Peralta V, Cuesta MJ, Zarzuela A, Serrano F, Martinez-Larrea A, Fananas L. 2004. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry 161(6):1110-1112.
36. Rybakowski JK, Borkowska A, Czerski PM, Dmitrzak-Weglarz M, Skibinska M, Kapelski P, Hauser J. 2006. Performance on the Wisconsin Card Sorting Test in schizophrenia and genes of dopaminergic inactivation (COMT, DAT, NET). Psychiatry Res 143(1):13-19.
37. Sasaki M, Kaneuchi M, Sakuragi N, Dahiya R. 2003. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res 63(12):3101-3106.
38. Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
39. Snitz BE, Macdonald AW III, Carter CS. 2006. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: A meta-analytic review of putative endophenotypes. Schizophr Bull 32(1):179-194.
40. Sullivan EV, Mathalon DH, Zipursky RB, Kersteen-Tucker Z, Knight RT, Pfefferbaum A. 1993. Factors of the Wisconsin Card Sorting Test as measures of frontal-lobe function in schizophrenia and in chronic alcoholism. Psychiatry Res 46(2):175-199.
41. Teunissen CE, van Boxtel MP, Jolles J, de Vente J, Vreeling F, Verhey F, Polman CH, Dijkstra CD, Blom HJ. 2005. Homocysteine in relation to cognitive performance in pathological and non-pathological conditions. Clin Chem Lab Med 43(10):1089-1095.
42. Trandafir A, Meary A, Schurhoff F, Leboyer M, Szoke A. 2006. Memory tests in first-degree adult relatives of schizophrenic patients: A meta-analysis. Schizophr Res 81(2-3):217-226.
43. Tunbridge EM, Harrison PJ, Weinberger DR. 2006. Catechol -O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 60(2):141-151.
44. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. 2001. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22(4):195-201.
45. Wechsler D. 1997. Wechsler Adult Intelligence Scale. 3rd edition. San Antonio: Harcourt Assessment, Inc.
46. Williams GV, Castner SA. 2006. Under the curve: Critical issues for elucidating D1 receptor function in working memory. Neuroscience 139(1):263-276.